TuHURA Biosciences Inc
🔔 Watch stock
Assessment
Our Rating
A journalistic assessment by our editorial team at the time of the deep dive — it rates the company, not the entry point. Not investment advice and not a solicitation to buy or sell.
We found at least one documented issue that threatens the company itself — regardless of how the stock is currently valued.
Why this colour
The going-concern qualification for 2025 and the nearly empty till ($3.6 million) are hard warning signals, as are Altman-Z deep in the red, Piotroski 3 of 9 and three insolvency scanners. At the same time the insider credit facility has defused the acute distress (runway "through the end of 2028") — at distress rates, with a pledge of assets and a perpetual royalty. The case is binary: an IFx-2.0 approval could lever the slim market value upward, a failure hits a company that has pledged its entire assets. The decision is yours.
What the thesis turns on
Assessment: Opportunities & Risks
TuHURA is not a case of substance versus story, but a pure bet with clear conditions: a fascinating cancer technology with a clear Phase 3 path on one side — on the other an auditor who doubted the company could survive for 2025, not a cent of revenue, $141 million in accumulated losses and a rescue that comes from a major shareholder: $50 million at 12 percent, secured against everything, including a perpetual royalty on the lead drug. The acute bankruptcy danger is defused — the price for it is a new, expensive clock that ticks. Not investment advice.
Technology & program
The ImmuneFx idea is fascinating: IFx-2.0 makes tumors look to the immune system like bacteria. For the lead candidate there is an unusually clear regulatory path — a Phase 3 trial agreed with the FDA (Special Protocol Assessment) in Merkel cell carcinoma via the accelerated approval pathway, Phase 3 since June 2025 (annual report 10-K 2025).
Going concern & liquidity
The auditor gave the 10-K 2025 a going-concern qualification; cash stood at only $3.6 million as of December 31, 2025, against $27.6 million of annual cash outflow. The $50 million credit facility of April 2026 defuses the acute distress (runway per the 10-Q "through the end of 2028"), but presupposes the facility can be drawn.
Rescue & governance
The credit facility comes from an insider (Parkview/K&V, an entity owned by major shareholder Vijay Patel, stake over 5%): 12% interest (plus 6% on default), secured by virtually all assets, including a 75-percent profit sweep and a perpetual royalty on future IFx-2.0 revenue. A rescue that secures survival and at the same time makes it more expensive.
Loss & dilution
No product revenue since inception; net loss up from $21.7 to $30.1 million, accumulated deficit $141.2 million. The share count multiplied within a year from 12.2 to 63.6 million — ongoing, heavy dilution, most recently intensified by the Kineta acquisition.
Market & momentum
Plus 178 percent in six months and plus 532 percent above the 52-week low, carried by approval and rescue hope; technical scanners read the rally as a top formation (Weinstein Stage 3). Only about 15 percent institutional and about 35 percent insider ownership — a thinly traded micro-cap paper with a binary outcome.
Worth Noting
TuHURA emerged in October 2024 from the reverse merger with Kintara Therapeutics (1-for-35 reverse stock split, name change from KTRA to HURA); price and share history before October 2024 belong to the predecessor shell. The 2013 IPO year listed in databases refers to this shell.
The disappearance of the going-concern qualification in the 10-Q as of March 31, 2026 rests on the $50 million credit facility agreed only after the 10-K (April 2026); its runway "through the end of 2028" presupposes, per the report, that the facility can be drawn.
Price, valuation and scanner figures dated to July 8, 2026 (about $2.60); analyses are evergreen, daily prices are not a buy argument.
Stock Watch
This analysis is as of August 26, 2026. Stock Watch will tell you what's changed at HURA since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 0.44 $ to 3.20 $ · Last price: 2.10 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| TuHURA Biosciences Inc HURA | 0.1 | – | 0.0 | – | – | – | -14.0 |
| Vertex Pharmaceuticals Inc VRTX | 130.6 | 31.3 | 24.5 | 55.0 | 38.1 | 9.6 | 33.4 |
| Regeneron Pharmaceuticals Inc REGN | 82.0 | 19.9 | 13.1 | 44.5 | 20.7 | 1.0 | 35.5 |
| Moderna Inc MRNA | 62.7 | – | 4.6 | -66.0 | -131.1 | -39.2 | 532.3 |
| argenx NV ARGX | 61.9 | 38.1 | 34.2 | 59.1 | 32.0 | 89.6 | 30.9 |
| Revolution Medicines Inc RVMD | 40.9 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 338.3 |
| BeiGene, Ltd. ONC | 40.0 | 63.1 | 34.1 | 88.9 | 19.1 | 40.2 | 6.4 |
| Alnylam Pharmaceuticals Inc ALNY | 32.6 | 61.8 | 28.4 | 79.7 | 23.0 | 65.2 | -48.1 |
| Royalty Pharma Plc RPRX | 32.5 | 31.8 | 19.6 | 95.8 | 100.3 | 5.1 | 68.6 |
| Median of companies shown | 40.9 | 34.9 | 19.6 | 57.0 | 21.8 | 7.3 | 33.4 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | – | -8 | -8 | – | -8 | 7 | 8 |
| 2018 | – | -11 | -11 | -9,344.22 | -10 | 5 | 7 |
| 2019 | – | -8 | -8 | -5,471.26 | -6 | 2 | 4 |
| 2020 | – | -8 | -9 | -1,529.16 | -8 | 0 | 3 |
| 2021 | – | -22 | -38 | -2,589.28 | -19 | 11 | 14 |
| 2022 | 0 | -23 | -23 | -814.29 | -7 | -1 | 6 |
| 2023 | 0 | -15 | -15 | -316.50 | -8 | 12 | 15 |
| 2024 | 0 | -8 | -8 | -11.05 | -12 | -2 | 4 |
| 2025 | 0 | -18 | -22 | -1.16 | -15 | 15 | 20 |
| 2026 | 0 | -32 | -30 | -0.63 | -28 | 21 | 27 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.09 | – | – | – | – | -3 | -3 |
| 2025: Q1 | -0.10 | – | 0 | – | – | -5 | -5 |
| 2025: Q2 | -0.15 | – | 0 | – | – | -6 | -6 |
| 2025: Q3 | -0.11 | – | 0 | – | – | -11 | -11 |
| 2025: Q4 | -0.11 | – | 0 | – | – | -6 | -6 |
| 2026: Q1 | -0.12 | – | 0 | – | – | -4 | -5 |
| 2026: Q2 | -0.14 | 6.70 | – | – | – | -9 | -9 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Momentum & Trend
Research
Risk & Weakness
- Bankruptcy Study: Stacked Warning Signals
- Going Concern (Distress Proxy)
- Insolvency Radar: Cash Running Low
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.53 | -0.55 – -0.51 | 0 | 19.3% | 2 |
| 12/31/2027 | -0.61 | -0.61 – -0.60 | 14 | -14.1% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Geprüft am 14.07.2026 gegen die Geschäftsberichte (10-K) für die Geschäftsjahre 2025 (eingereicht 31.03.2026) und 2024 (31.03.2025) sowie die vier jüngsten Quartalsberichte (10-Q) bis zum 31.03.2026. TuHURA Biosciences ist ein immunonkologisches Unternehmen in der klinischen Phase (Multi-Indikations-Immunmodulator-Plattform ImmuneFx; Leitwirkstoff IFx-2.0, ein Innate-Immune-Agonist, gegen Merkelzellkarzinom als Zusatztherapie zu Pembrolizumab). In sämtlichen ausgewerteten SEC-Filings kommen die Begriffe „artificial intelligence“ und „machine learning“ kein einziges Mal vor (Trefferzahl 0 in 10-K 2025, 10-K 2024 und den 10-Qs). Es gibt keine KI-Produkte oder -Dienste als Umsatzquelle (das Unternehmen erzielt überhaupt keinen Produktumsatz), keinen dokumentierten operativen KI-Einsatz — etwa in der Wirkstoff-Forschung — und kein konkretes KI-Geschäftsrisiko für das eigene Modell. Die Technologie ist ausschließlich biologisch (Zell- und Gentherapien, pDNA-basierte innate-immune-Agonisten, bispezifische Antikörper-Wirkstoff-Konjugate gegen MDSCs). Damit bleibt es beim dokumentierten Negativ-Befund „neutral“: kein wesentlicher KI-Bezug in den Pflichtdokumenten.
View the full file — quotes, sources, reviewed filings
„We employ a multi-indication immunomodulator platform (ImmuneFx) that utilizes both cell and gene therapies, together, to stimulate the immune system to recognize and combat tumor cells."
Wir setzen eine Multi-Indikations-Immunmodulator-Plattform (ImmuneFx) ein, die sowohl Zell- als auch Gentherapien nutzt, um das Immunsystem dazu zu bringen, Tumorzellen zu erkennen und zu bekämpfen.
10-K · 2026-03-31 · View SEC filing
„IFx-2.0 innate immune agonist, our lead product candidate, is comparatively simple to administer and involves only the injection into a patient's tumor, or lymph node, of a relatively small amount of pDNA that is designed to encode for an immunogenic gram positive bacterial protein that gets expressed on the surface of the patient's tumor so that the surface of the tumor looks like a bacterium."
IFx-2.0, unser wichtigster Wirkstoffkandidat und ein Innate-Immune-Agonist, ist vergleichsweise einfach zu verabreichen und erfordert nur die Injektion einer relativ kleinen Menge pDNA in den Tumor oder Lymphknoten eines Patienten; diese pDNA ist so konstruiert, dass sie ein immunogenes Eiweiß eines grampositiven Bakteriums codiert, das auf der Tumoroberfläche ausgeprägt wird, sodass der Tumor für das Immunsystem wie ein Bakterium aussieht.
10-K · 2026-03-31 · View SEC filing
Filings Reviewed: 10-Q 2026-05-15 · 10-Q 2025-11-14 · 10-Q 2025-08-14 · 10-Q 2025-05-15 · 10-K 2026-03-31 · 10-K 2025-03-31
Rated on July 14, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 0.0%
- Share count grows by less than 3% a year 911.2%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 39.3%
- Net debt below twice EBITDA 3 m net cash
- Operating cash flow covers the profits of the last three years 6 m
- Return on capital at 15% or higher, or up versus two years ago -148.3%
- Insiders hold at least 10% or are net buyers 34.7%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% –
- ROCE > 15% -148.4%
- Expected return > 10% –
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
The company
About the Company
TuHURA Biosciences, Inc., ein immunonkologisches Unternehmen in der klinischen Phase, entwickelt neuartige Technologien zur Behandlung mit Krebsimmuntherapien.
- Employees
- 22
- Headquarters
- Tampa, FL
- Address
- 10500 University Center Drive, 33612 Tampa, United States
- Phone
- 813 875 6600
- Website
- tuhurabio.com
- IPO Date
- 02/22/2013
- ISIN
- US8989201038
- Stock Split
- 1:35 on 10/18/2024
- Stock Split
- 1:50 on 11/14/2022
- Stock Split
- 1:10 on 05/08/2019
Management
| Name | Title | Birth Year |
|---|---|---|
| James A. Bianco M.D. | President, CEO & Director | 1957 |
| Dan Dearborn CPA | Executive VP of Finance & CFO | 1967 |
| Michael Lawman | Co-Founder | – |
| Patricia Lawman | Co-Founder | – |
| Michael Krsulich | Head of Quality Assurance | – |
| Amanda Garofalo | Senior Vice President of Clinical Operations | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 09/17/2026 TuHURA Biosciences, Inc./NV (HURA): Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Financial Statements and Exhibits SEC ↗
- 09/16/2026 TuHURA Biosciences, Inc./NV (HURA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Financial Statements and Exhibits SEC ↗
- 09/04/2026 TuHURA Biosciences, Inc./NV (HURA): Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Financial Statements and Exhibits SEC ↗
- 08/21/2026 TuHURA Biosciences, Inc./NV (HURA): Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Financial Statements and Exhibits SEC ↗
- 08/19/2026 TuHURA Biosciences, Inc./NV (HURA): Unregistered Sales of Equity Securities; Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits SEC ↗
- 08/14/2026 TuHURA Biosciences, Inc./NV (HURA): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
- 08/13/2026 TuHURA Biosciences, Inc./NV (HURA): Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Financial Statements and Exhibits SEC ↗
- 07/29/2026 TuHURA Biosciences, Inc./NV (HURA): Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Financial Statements and Exhibits SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.